Votre navigateur ne supporte pas le javascript Wallonia & Brussels against COVID-19 - See all

See all

Eric Haubruge, Professeur ordinaire

ULiège
" Development of Methods for Mask and N95 Decontamination (the DeMaND study) and reuse for healthcare workers at the frontline The aim of this study is to identify and test, simple low-cost safe decontamination methods to enable medical masks and N95/ FFP2 respirators reuse in healthcare settings where there are critical shortages. "
Funding: Open Philanthropy
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it. 

Eric Haubruge, Professeur ordinaire - Etienne Thiry, Professeur ordinaire - Georges Daube, Professeur ordinaire

ULiège
"DECONTAMINATION AND REUSE OF SURGICAL MASKS AND FILTERING FACEPIECE RESPIRATORS The global test protocol, presented in this project, aims to assess: a) the effectiveness of several decontamination methods with regard to integrity (""barrier"" function) and the quality of surgical masks and filtering facepiece respirators FFP2/N95; b) the efficacy of these decontamination methods on the inactivation of a coronavirus, similar to the SARS-CoV-2 virus present on surgical masks and filtering facepiece respirators FFP2/N95. Moreover, the present project aims to set up a consortium of companies and laboratories to meet the diverse and varied requests for ""reuse"" of various medical protective equipment (masks, filters, clothing, etc.) linked with the environmental approach."
Funding: Walloon Government
Contact: https://www.news.uliege.be/cms/c_11717821/fr/l-uliege-coordonne-le-projet-wallon-de-decontamination-des-masques-chirurgicaux-et-de-protection-respiratoire-ffp2...

Etienne CAVALIER, Professor

ULiège, CHU de Liège, CIRM
" This study aims at measuring the activity of the Angiotensin-2 enzyme (AT2) by LCMS./MS in COVID patients. This enzyme plays a key-role in the mechanisms of the infection by the SARS-COV2 "
Funding: Fondation Leon Fredericq
Contact: Professor Etienne Cavalier Department of Clinical Chemsitry University of Liège, CHU de Liège This email address is being protected from spambots. You need JavaScript enabled to view it.

Fabrice JOURNE, Doctor - Alexandre LEGRAND, Professor - Jean-Marie COLET, Professor

UMONS 
" Development of a Covid-19 serum library within the UMONS biobank. Collection and storage of samples (serum, blood or urine samples as well as nasopharyngeal samples) from patients diagnosed with Covid-19 positive or negative by an RT-PCR test. Collaboration between UMONS and Ambroise-Paré hospital (Mons) as well as Epicura hospital network (Baudour, Hornu). "
Funding: UMONS logistic and fiinancial supports
Contact: UMONS Biobank Prof. A. legrand, Manager Dr. F. Journe, Coordinator

Florence SCHLEICH, MD, PhD

ULiege, CHU, GIGA I3
" Are obstructive diseases risk factors for developing pulmonary complications due to COVID19? We will include all patients followed up at CHU of Liege for COVID19 infection and classify them according to their underlying bronchopulmonary disease. The aim is to evaluate if asthma, severe asthma or chronic obstructive pulmonary diseases represent risk factors for developing pulmonary complications during COVID 19 infection. We want to find out biological or clinical predictors of complications. We also want to evaluate efficacy and safety of inhaled corticosteroids in asthma in case of COVID infection. Biomarkers will be measured at baseline and during follow-up. "
Funding: Fonds Leon Frederic
Contact: Schleich Florence, MD, PhD This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it.

François Dufrasne, Dr. - Benoit Kabamba-Mukadi, Pr.

UCLouvain
" This study aims to assess the potential roles of spike glycoproteins and viral proteins encoded by ORF6, ORF7a, ORF8 and ORF10 in the antagonism of several known restriction factors (BST-2, GBP5, IFITM, ...) and in the modulation of innate immune responses (NF-kB pathway and IFN response). These proteins will be expressed in different cell models and we will define their ability to bind and/or degrade restriction factors. Depending on results, we will perform sequencing (NGS) of these genes from clinical isolates in order to observe whether the genetic variability can be linked to the pathogenesis of SARS-CoV-2 viruses. "
Funding: Own funds
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Francois Dupont, Team Leader - Jean-Michel Redouté, Professor - Samuel Dricot, Technician - Gabriel Digregorio, Teaching assistant/ PhD Student

ULiège
“ Microsys Laboratory takes part in 3D printing of protective visor elements for care staff. This activity is enabled by the recent acquisition of a high-performance 3D printer and takes place within the framework of an ongoing project aimed at developing technologies in the field of microsystems, sensors and packaging.”
Funding: Projets compléments FEDER Micro+ (conventions 1510608 et 1510609)
Contact: Francois Dupont - This email address is being protected from spambots. You need JavaScript enabled to view it.

François Fuks, Full Professor

Laboratory of Cancer Epigenetics, ULB, Faculty of Medicine - Royal Academy of Medicine of Belgium
" In recent years epigenetics has become an essential component of biological research, playing key roles in many physiopathological conditions. Recent work in viral epigenetics highlighted these modifications as an essential mechanism in modulating many viruses life cycles. To date, whether this holds true also for SARS-CoV-2 remains unknown, let alone the potential use of epigenetics inhibitors as novel antiviral therapy against SARS-CoV-2. • To address these unanswered questions and to respond to the current international urge of new therapeutic approaches against COVID-19, our study, which would uncover a link between epigenetics and SARS-CoV-2, aim to provide innovative advances for SARS-CoV-2 biology and therapy: • Overall, we will generate a comprehensive dataset aiming at expanding further our understanding of the biological functions of epigenetic modifications in the SARS-CoV-2...

Francois Mullier, Prof - Alain Dive, Prof - Michael Hardy, Dr - Sarah Lessire, Prof - Isabelle Michaux, Prof - Jonathan Douxfils, Prof

UCLouvain, CHU UCLouvain/UNamur
" Evaluation of the thrombotic risk associated with SARS-CoV-2 infection and its management in the intensive care unit: a clinical and biological longitudinal study. Background Since the beginning of SARS-CoV-2 outbreak in December 2019, data accumulate regarding the high thrombotic risk associated with this infection, which could explain substantial part of the observed morbidity and mortality (1). Accordingly, a retrospective study suggested that prophylactic anticoagulation could reduce mortality in severe COVID-19 patients with sepsis-induced coagulopathy (2). Furthermore, a European cohort reported a 27% incidence of venous thrombo-embolisms (VTEs) despite systematic prophylactic anticoagulation, raising the question whether deeper anticoagulant regimen would be beneficial in severe COVID-19 (3). Some authors also suggested that fibrinolysis alterations could be a significant determinant of SARS-CoV-2 infection's prognosis, as it is in...

Frédéric Silvestre, Professor

UNamur
" The main scientific question of this project aims to understand this inter-individual variability in the response to 2019-nCoV in human population, first during ageing process, second among population of same age. The first hypothesis that will be tested in this project is that epigenetic differences among human population can, at least partly, explain differences in the individual responses to SARS-CoV-2, and that this virus differentially affects the epigenome of different individuals during the infection. The second hypothesis that will be tested is that changes in the epigenome during ageing could increase the susceptibility of patients to SARS-CoV-2. "
Funding: To be searched
Publication References: - Fellous A, Earley RL, Silvestre F. Identification and expression of mangrove rivulus (Kryptolebias marmoratus) histone deacetylase (HDAC) and lysine acetyltransferase (KAT) genes. Gene, 691 (2019), 56-69. - Fellous A, Earley RL, Silvestre F. The Kdm/Kmt gene families in...

Géraldine Dessilly, PhD - Benoît Kabamba, Professor

UCLouvain/IREC/MBLG
" The objective of this project is to perform SARS CoV-2 infection of cells from Vero E6 line. With a view to -Study the information of the infection on the immune activation pathways and the metabolic pathways within the cells - Perform virus viability assays in different environments and analyze the effectiveness of the hygiene measures taken to prevent transmission of the virus into the environment. - Study the neutralization and the cytopathogenic effect by antibodies from clinical samples "
Funding: own funding
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it., Professor UCLouvain/Cliniques universitaires St-Luc This email address is being protected from spambots. You need JavaScript enabled to view it., PhD UCLouvain

Gilles Darcis, FNRS Post-doctorate Clinical Master Specialist

ULiège, CHU - FNRS
" We aim to define the clinical characteristics associated with the production and the level of neutralizing antibodies (NAbs) in COVID19 recovered patients. In particular, we will investigate whether the development of a strong and persistent humoral immune response takes place in severely affected, individuals with mild symptoms or asymptomatic individuals. We will also study the study the persistence of NAbs overtime. "
Funding: Fonds Léon Frédéricq FNRS
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Gilles Parzibut, Doctor

ULiège, CHU
" La recherche de biomarqueurs fiables, sensibles et peu invasifs est un enjeu de premier ordre pour la médecine moderne. En effet, ces biomarqueurs ont le potentiel de transformer la prise en charge médicale en améliorant le dépistage et le diagnostic, mais aussi en permettant de mieux appréhender la physiopathologie d'une pathologie ou sa réponse à un traitement donné. Fort de nos travaux précédents, nous proposons de réaliser une étude prospective sur une population adulte souffrant d'un SDRA modéré à sévère post SARS-COV2 afin de caractériser une signature exosomique plasmatique propre à cette population. "
Funding: FLF FIRS CHU de Liège
Publication References: hankar-Hari, M., Fan, E. & Ferguson, N. D. Acute respiratory distress syndrome (ARDS) phenotyping. Intensive Care Med. (2018). 45;(4): 516-519. Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. N Engl J Med. 2017;377(6):562–72. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle...

Gregory Ponthiere, Professor

UCLouvain
" This research project aims at studying the conditions under which the modern welfare state could build a kind of epidemics insurance, while paying a particular attention to the issue of fairness. The global objective of saving lives may be associated to policies that have undesirable distributive effects, against ideals of social justice. The project aims at finding ways to make mass prevention and equity compatible. "
Funding: This project will be part of my research load at UCLouvain, within the Hoover Chair in Economic ans Social Ethics.
Publication References: Fleurbaey, M., Ponthiere, G. (2013). Prevention against Equality ? Journal of Public Economics. Fleurbaey, M., Leroux, ML, Ponthiere, G. (2014). Compensating the dead. Journal of Mathematical Economics. Fleurbaey, M., Leroux, ML., Pestieau, P., Ponthiere G. (2016). Fair retirement under risk lifetime. International Economic Review. Leroux, ML., Ponthiere, G. (2018). Working time regulations, unequal lifetime and...

Guy Jerusalem, Professor

CHU Liege/ULiège
" La nouvelle pandémie COVID-19 modifie la prise en charge des patients oncologiques. Le premier objectif de notre projet est d'étudier la sécurité de la poursuite des traitements systémiques anti-tumoraux dans le contexte actuel de pandémie. Le deuxième objectif est de comprendre les inquiétudes et les ressentis de nos patients par rapport au risque d'attraper l'infection et leurs conséquences. Le troisième objectif est d'évaluer le taux d'infection et de séroconversion asymptomatique chez nos patients en comparaison à la population globale. Le quatrième objectif est de mieux comprendre les raisons de détresse du personnel soignant en oncologie afin de mieux organiser des mesures de soutien psychologique. "
Funding: Fondation Leon Frederic Fonds propres Oncologie Médicale
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Contact us

c/o F.R.S. - FNRS

Rue d’Egmont 5

B - 1000 Bruxelles

Tél : +32 2 504 92 11

info@COVID19-WB.be

Brussels & Wallonia against COVID19